ORBIMED ADVISORS LLC
Q4 2021 13F-HR Holdings
Net value change ($000)
-1,320,875
(-14.5%)
New positions
12
Sold out positions
23
Turnover %
13.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Theseus Pharmaceuticals, Inc. | 213,514 | NEW |
| PFE | 154,439 | NEW |
| ACET | 73,544 | 129.7% |
| CMPX | 68,608 | NEW |
| BMRN | 67,488 | 787.4% |
| Seagen Inc. | 55,850 | 122.7% |
| Tricida, Inc. | 53,676 | 120.3% |
| HCA | 53,031 | 112.7% |
| SNDX | 39,729 | 1090.9% |
| SYK | 35,452 | 39.8% |
Top Reduces (Value $000, Stocks/ETFs)
| IVVD | -191,219 | -84.1% |
| PRLD | -188,746 | -60.2% |
| MRK | -143,975 | -51.4% |
| ELV | -77,207 | -100.0% |
| Deciphera Pharmaceuticals, Inc. | -74,183 | -100.0% |
| PGNY | -71,123 | -100.0% |
| CRSP | -68,580 | -100.0% |
| Gracell Biotechnologies Inc. | -61,738 | -56.5% |
| Turning Point Therapeutics, Inc. | -56,385 | -35.9% |
| ImmunoGen, Inc. | -55,765 | -66.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|